Pressure to cut development costs and lower regulatory barriers while assuring product quality has stimulated the pharmaceutical industry to apply Quality by Design (QbD) to manage risk and gain process and product understanding. As a result, QbD is being widely promoted by regulatory authorities such as the Food and Drug Administration, and the International Conference on Harmonization.
Making sure your data and processes from research and development through to production are compliant is essential in today's highly regulated life science, biopharma, pharmaceutical and food industries. But it's no easy task. Following all of the required steps and ensuring the integrity of your data at every stage is easier and more successful when you use a product designed to keep your data compliant.
Using a Quality by Design (QbD) approach for DOE supports ICH Q8 compliance
In pharmaceutical development, manufacturers must be able to demonstrate product robustness and deliver the intended quality of the product within allowable ranges for the claimed shelf-life period. Both international and country specific regulatory agencies, such as the FDA, pay close attention to these claims.